高抗扭转强度支架治疗股浅动脉病变:前瞻性Q3登记研究
该前瞻性、多中心、观察性上市后监测研究在德国9个中心连续纳入199例症状性股浅动脉原发病变患者,评估POLARIS高抗扭转强度自膨胀支架的有效性与安全性。12个月免于临床驱动靶病变血运重建率为94.4%(95%CI 90.6-98.2),24个月为88.7%(95%CI 83.0-94.4),结论认为该支架在真实世界中中期有效且未提出安全性担忧。
要点
- 12个月免于cdTLR为94.4%(95%CI 90.6-98.2),24个月为88.7%(95%CI 83.0-94.4)。
- 手术成功率为96.2%,12和24个月主要临床改善分别为87.5%和85.4%。
- 12和24个月免于MACLE分别为94.8%(95%CI 91.4-98.1)和93.8%(95%CI 89.9-97.6)。
核心结论
- 在真实世界环境中使用高双向抗扭转强度的POLARIS支架治疗股浅动脉闭塞性疾病中期有效,且未提出任何安全性担忧。
研究设计与样本
- 前瞻性、多中心、观察性上市后监测研究,2014年12月至2018年8月在德国9个中心连续纳入199例接受POLARIS支架植入的症状性股浅动脉原发病变患者。
- 主要结局指标为12个月免于临床驱动靶病变血运重建(cdTLR)。
- 主要次要结局为手术成功、主要临床改善及24个月免于主要不良心血管和肢体事件(MACLE)。
主要发现
- 患者年龄70±11岁,男性占70.4%,当前吸烟者占52.6%,糖尿病占37.6%,肥胖占25.0%,间歇性跛行占88.4%。
- 病变平均长度98±83 mm,闭塞病变占43.5%,严重钙化占27.3%。
- 12个月免于cdTLR为94.4%(95%CI 90.6-98.2),24个月为88.7%(95%CI 83.0-94.4)。
- 手术成功率为96.2%,12和24个月主要临床改善分别为87.5%和85.4%。
- 12和24个月免于MACLE分别为94.8%(95%CI 91.4-98.1)和93.8%(95%CI 89.9-97.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This postmarketing surveillance study aimed to assess effectiveness and safety of a peripheral self-expanding stent with high torsional strength (POLARIS stent) for the treatment of de novo superficial femoral artery (SFA) lesions in the routine clinical practice. MATERIALS AND METHODS: Consecutive patients with symptomatic de novo SFA occlusive disease who underwent POLARIS stent implantation were enrolled into the prospective, multicenter, observational postmarket surveillance study. Primary outcome measure was freedom from clinically driven target lesion revascularization (cdTLR) at 12 months. Main secondary outcomes were procedural success, primary clinical improvement, and freedom from major adverse cardiovascular and limb events (MACLE) throughout 24 months. RESULTS: A total of 199 participants (70±11 years, 70.4% men) were included in the study at 9 German sites from December 2014 to August 2018. Half of them (52.6%) were current smokers, 37.6% had diabetes, and 25.0% were obese. Most participants suffered from intermittent claudication (88.4%). Mean lesion length was 98±83 mm, 43.5% of lesions were occluded, and 27.3% were severely calcified. Freedom from 12 months cdTLR was 94.4% (95% confidence interval [CI], 90.6-98.2). At 24 months, freedom from cdTLR was 88.7% (95% CI, 83.0-94.4). Procedural success was achieved in 96.2% of participants. Primary clinical improvement occurred in 87.5% and 85.4% of participants at 12 and 24 months, respectively. Freedom from MACLE was 94.8% (95% CI, 91.4-98.1) and 93.8% (95% CI, 89.9-97.6) at 12 and 24 months, respectively. CONCLUSIONS: Treatment of SFA occlusive disease in a real-world setting using the POLARIS stent with high bidirectional torsional strength is efficacious and does not raise any safety concern in the medium term. The study is registered with ClinicalTrials.gov (Identifier: NCT02307292).
引用
- Thieme M, Arjumand J, Spanagel M, et al. Stents With Torsional Strength for Superficial Femoral Artery Disease: The Prospective Q3-Registry. J Endovasc Ther. 2022. PMID: 34994234. doi:10.1177/15266028211067726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。